Bacteriotherapy for inflammatory bowel disease
Abstract The number of patients with inflammatory bowel disease is rapidly increasing in developed countries. The main cause of this increase is thought not to be genetic, but secondary to rapidly modernized environmental change. Changes in the environment have been detrimental to enteric probiotics...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-01-01
|
| Series: | Inflammation and Regeneration |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41232-020-00153-4 |
| _version_ | 1818383097226330112 |
|---|---|
| author | Yusuke Yoshimatsu Yohei Mikami Takanori Kanai |
| author_facet | Yusuke Yoshimatsu Yohei Mikami Takanori Kanai |
| author_sort | Yusuke Yoshimatsu |
| collection | DOAJ |
| description | Abstract The number of patients with inflammatory bowel disease is rapidly increasing in developed countries. The main cause of this increase is thought not to be genetic, but secondary to rapidly modernized environmental change. Changes in the environment have been detrimental to enteric probiotics useful for fermentation, inducing an increase in pathobionts that survive by means other than fermentation. This dysregulated microbiota composition, the so-called dysbiosis, is believed to have increased the incidence of inflammatory bowel disease. Bacteriotherapy, a treatment that prophylactically and therapeutically corrects the composition of disturbed intestinal microbiota, is a promising recent development. In fact, fecal microbiome transplantation for recurrent Clostridioides difficile infection in 2013 was a significant contribution for bacteriotherapy. In this paper, we comprehensively review bacteriotherapy in an easy-to-understand format. |
| first_indexed | 2024-12-14T03:00:57Z |
| format | Article |
| id | doaj.art-ffa1759fc0d845d2a5789ea9c466d884 |
| institution | Directory Open Access Journal |
| issn | 1880-8190 |
| language | English |
| last_indexed | 2024-12-14T03:00:57Z |
| publishDate | 2021-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Inflammation and Regeneration |
| spelling | doaj.art-ffa1759fc0d845d2a5789ea9c466d8842022-12-21T23:19:31ZengBMCInflammation and Regeneration1880-81902021-01-014111810.1186/s41232-020-00153-4Bacteriotherapy for inflammatory bowel diseaseYusuke Yoshimatsu0Yohei Mikami1Takanori Kanai2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of MedicineAbstract The number of patients with inflammatory bowel disease is rapidly increasing in developed countries. The main cause of this increase is thought not to be genetic, but secondary to rapidly modernized environmental change. Changes in the environment have been detrimental to enteric probiotics useful for fermentation, inducing an increase in pathobionts that survive by means other than fermentation. This dysregulated microbiota composition, the so-called dysbiosis, is believed to have increased the incidence of inflammatory bowel disease. Bacteriotherapy, a treatment that prophylactically and therapeutically corrects the composition of disturbed intestinal microbiota, is a promising recent development. In fact, fecal microbiome transplantation for recurrent Clostridioides difficile infection in 2013 was a significant contribution for bacteriotherapy. In this paper, we comprehensively review bacteriotherapy in an easy-to-understand format.https://doi.org/10.1186/s41232-020-00153-4DysbiosisClostridioides (Clostridium) difficile infectionFecal microbiome transplantationPrebioticsProbioticsBacteriotherapy |
| spellingShingle | Yusuke Yoshimatsu Yohei Mikami Takanori Kanai Bacteriotherapy for inflammatory bowel disease Inflammation and Regeneration Dysbiosis Clostridioides (Clostridium) difficile infection Fecal microbiome transplantation Prebiotics Probiotics Bacteriotherapy |
| title | Bacteriotherapy for inflammatory bowel disease |
| title_full | Bacteriotherapy for inflammatory bowel disease |
| title_fullStr | Bacteriotherapy for inflammatory bowel disease |
| title_full_unstemmed | Bacteriotherapy for inflammatory bowel disease |
| title_short | Bacteriotherapy for inflammatory bowel disease |
| title_sort | bacteriotherapy for inflammatory bowel disease |
| topic | Dysbiosis Clostridioides (Clostridium) difficile infection Fecal microbiome transplantation Prebiotics Probiotics Bacteriotherapy |
| url | https://doi.org/10.1186/s41232-020-00153-4 |
| work_keys_str_mv | AT yusukeyoshimatsu bacteriotherapyforinflammatoryboweldisease AT yoheimikami bacteriotherapyforinflammatoryboweldisease AT takanorikanai bacteriotherapyforinflammatoryboweldisease |